Literature DB >> 12607051

Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: comparison with intraarterial digital subtraction angiography.

Moon-Gyu Lee1, Kwang Bo Park, Yong Moon Shin, Hyun Ki Yoon, Kyu Bo Sung, Myung Hwan Kim, Sung Gyu Lee, Eun Mee Kang.   

Abstract

We sought to evaluate the image quality of double-dose, contrast-enhanced 3D fast imaging with steady-state precession (FISP) magnetic resonance (MR) angiography in patients with hilar cholangiocarcinoma, and to compare its efficacy with intraarterial digital subtraction angiography (DSA). Thirty-six patients were studied to determine the visibility of the hepatic artery and portal vein with contrast-enhanced MR angiography. Determination of hepatic arterial and/or portal invasion from cholangiocarcinoma was compared between MR angiography and DSA as well. 0.2 mmol/kg gadolinium chelates were administrated at a rate of 4 ml/s. The hepatic artery was diagnostically visible in 28 patients (78%); the portal vein, in 34 patients (94%). The sensitivities, specificities, and accuracies in distinguishing arterial invasion, were 58%, 93%, and 89%, respectively, with MR angiography; 75%, 99%, and 96%, respectively, with DSA. In distinguishing portal venous invasion, these were 78%, 91%, and 89%, respectively, with MR angiography; 78%, 92%, and 90%, respectively, with DSA. There were no significant differences between imaging methods ( p >.05); however, DSA was superior in specificity regarding hepatic arterial invasion ( p =.0143). The data presented here indicate that noninvasive contrast-enhanced 3D FISP MR angiography has the potential to replace DSA in the preoperative evaluation of hilar cholangiocarcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 12607051     DOI: 10.1007/s00268-002-6701-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  14 in total

1.  [Radiological diagnosis of Klatskin's tumour].

Authors:  S Pauls; M S Juchems; H-J Brambs
Journal:  Radiologe       Date:  2005-11       Impact factor: 0.635

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

Review 3.  Palliation: Hilar cholangiocarcinoma.

Authors:  Mahesh Kr Goenka; Usha Goenka
Journal:  World J Hepatol       Date:  2014-08-27

Review 4.  Cholangiocarcinoma: modern advances in understanding a deadly old disease.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  J Hepatol       Date:  2006-09-25       Impact factor: 25.083

5.  Value of Multidetector-row Computed Tomography in Diagnosis of Portal Vein Invasion by Perihilar Cholangiocarcinoma.

Authors:  Teiichi Sugiura; Hideki Nishio; Masato Nagino; Yoshiki Senda; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Koji Oda; Yuji Nimura
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

Review 6.  Cross-sectional imaging of biliary tumors: current clinical status and future developments.

Authors:  Christoph J Zech; Stefan O Schoenberg; Maximilian Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2004-04-23       Impact factor: 5.315

7.  Hilar cholangiocarcinoma: diagnosis and staging.

Authors:  William Jarnagin; Corinne Winston
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 8.  Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice.

Authors:  Takashi Tajiri; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Shigeki Yokomuro; Yoshiaki Mizuguchi
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 9.  Cholangiocarcinoma: a compact review of the literature.

Authors:  Yucel Ustundag; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

10.  Staging cholangiocarcinoma by imaging studies.

Authors:  V Vilgrain
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.